LT3273957T - Biotinas, skirtas demielinizuojančių neuropatijų gydymui - Google Patents

Biotinas, skirtas demielinizuojančių neuropatijų gydymui

Info

Publication number
LT3273957T
LT3273957T LT16713833T LT16713833T LT3273957T LT 3273957 T LT3273957 T LT 3273957T LT 16713833 T LT16713833 T LT 16713833T LT 16713833 T LT16713833 T LT 16713833T LT 3273957 T LT3273957 T LT 3273957T
Authority
LT
Lithuania
Prior art keywords
demielinizing
neuropathies
biotin
treatment
demielinizing neuropathies
Prior art date
Application number
LT16713833T
Other languages
English (en)
Lithuanian (lt)
Inventor
Frédéric Sedel
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3273957(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of LT3273957T publication Critical patent/LT3273957T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Magnetic Ceramics (AREA)
  • Manufacture, Treatment Of Glass Fibers (AREA)
  • Farming Of Fish And Shellfish (AREA)
LT16713833T 2015-03-26 2016-03-25 Biotinas, skirtas demielinizuojančių neuropatijų gydymui LT3273957T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305437.4A EP3072513A1 (en) 2015-03-26 2015-03-26 Biotin for treating Amyotrophic lateral sclerosis
PCT/EP2016/056696 WO2016151132A1 (en) 2015-03-26 2016-03-25 Biotin for treating amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
LT3273957T true LT3273957T (lt) 2019-11-11

Family

ID=52779582

Family Applications (1)

Application Number Title Priority Date Filing Date
LT16713833T LT3273957T (lt) 2015-03-26 2016-03-25 Biotinas, skirtas demielinizuojančių neuropatijų gydymui

Country Status (24)

Country Link
US (2) US10357480B2 (enExample)
EP (2) EP3072513A1 (enExample)
JP (1) JP6752874B2 (enExample)
KR (1) KR20170131543A (enExample)
CN (2) CN111973592A (enExample)
AU (1) AU2016238759B2 (enExample)
BR (1) BR112017020408A2 (enExample)
CA (1) CA2980660A1 (enExample)
CY (1) CY1122374T1 (enExample)
DK (1) DK3273957T3 (enExample)
EA (1) EA034394B1 (enExample)
ES (1) ES2748354T3 (enExample)
HR (1) HRP20191491T1 (enExample)
HU (1) HUE046116T2 (enExample)
IL (1) IL254619B (enExample)
LT (1) LT3273957T (enExample)
MA (1) MA41809B1 (enExample)
ME (1) ME03567B (enExample)
PL (1) PL3273957T3 (enExample)
PT (1) PT3273957T (enExample)
RS (1) RS59149B1 (enExample)
SI (1) SI3273957T1 (enExample)
SM (1) SMT201900548T1 (enExample)
WO (1) WO2016151132A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3275439A1 (en) 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
AU2019396829B2 (en) * 2018-12-11 2025-04-17 Myospots Australia Pty Ltd Adhesive pad
CN112386703A (zh) * 2020-01-15 2021-02-23 李启芳 治疗als的联合用药物及其应用
US20240082296A1 (en) * 2020-10-09 2024-03-14 Tx Medic Ab Treatment of muscle atrophy using dextran sulfate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
WO2004028472A2 (en) 2002-09-27 2004-04-08 Biogen Idec Ma Inc. THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
US20130004545A1 (en) 2009-12-23 2013-01-03 Lupin Limited Slow release pharmaceutical compositions of iloperidone
FR2958166B1 (fr) 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
JP6152090B2 (ja) * 2011-04-21 2017-06-21 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate 視神経脊髄炎を処置するための組成物および方法
US10272082B2 (en) * 2011-07-13 2019-04-30 Cytokinetics, Inc. Combination ALS therapy
WO2014177286A1 (en) 2013-04-29 2014-11-06 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
JP6664956B2 (ja) * 2015-02-27 2020-03-13 キリンホールディングス株式会社 筋分化促進組成物
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
EA201792124A1 (ru) 2018-04-30
RS59149B1 (sr) 2019-09-30
EP3273957B1 (en) 2019-08-14
DK3273957T3 (da) 2019-11-11
MA41809B1 (fr) 2019-12-31
CA2980660A1 (en) 2016-09-29
SMT201900548T1 (it) 2019-11-13
IL254619B (en) 2020-03-31
CY1122374T1 (el) 2021-01-27
SI3273957T1 (sl) 2019-11-29
AU2016238759B2 (en) 2020-08-06
WO2016151132A1 (en) 2016-09-29
PT3273957T (pt) 2019-09-18
ME03567B (me) 2020-07-20
EP3273957A1 (en) 2018-01-31
CN111973592A (zh) 2020-11-24
US20190314342A1 (en) 2019-10-17
CN107405335A (zh) 2017-11-28
US20180125825A1 (en) 2018-05-10
IL254619A0 (en) 2017-11-30
JP6752874B2 (ja) 2020-09-09
HUE046116T2 (hu) 2020-02-28
BR112017020408A2 (pt) 2018-06-05
AU2016238759A1 (en) 2017-10-05
JP2018512451A (ja) 2018-05-17
EA034394B1 (ru) 2020-02-04
HRP20191491T1 (hr) 2019-11-15
US10357480B2 (en) 2019-07-23
KR20170131543A (ko) 2017-11-29
ES2748354T3 (es) 2020-03-16
EP3072513A1 (en) 2016-09-28
PL3273957T3 (pl) 2020-01-31
MA41809A (fr) 2018-01-30
NZ735528A (en) 2021-09-24

Similar Documents

Publication Publication Date Title
PL3265053T3 (pl) Sposoby leczenia skóry
EP3601536A4 (en) TREATMENT PROCESSES
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
LT3230281T (lt) 1,3-tiazol-2-ilu pakeisti benzamidai
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
EP3345473A4 (en) HARVESTER
IL256206A (en) Mct4 inhibitors for treating disease
DK3262182T3 (da) Modificeret creatinase
LT3353177T (lt) Tricikliniai heterociklai, skirti vėžio gydymui
LT3294769T (lt) Daugybinei mielomai (dm) skirtas gydymas
EP3351087A4 (en) HARVESTER
PL3978074T3 (pl) Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
LT3113778T (lt) Piridazino dariniai, skirti naudoti ataksinio sutrikimo profilaktikai arba gydymui
EP3373875A4 (en) BANDAGE
DK3302478T3 (da) Pac-1 kombinations behandling
EP3597225A4 (en) TREATMENT PROCESS
EP3305185A4 (en) SPHYGMOMANOMETER
LT3273957T (lt) Biotinas, skirtas demielinizuojančių neuropatijų gydymui
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
LT3253749T (lt) Junginiai, pasižymintys priešnavikiniu aktyvumu
EP3272204A4 (en) HARVESTER